|Day Low/High||40.70 / 42.30|
|52 Wk Low/High||38.53 / 110.00|
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.
Investors in AnaptysBio Inc saw new options begin trading this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APPF, BLBD, BOJA, EROS, GAIA, ICD, LOB, TLRA, WMIH, XL, Y Downgrades: CLD, FUL, GOV, HZN, KOSS, NAP, OKE, STN Initiations: ANAB Read on to get TheStreet Quant Ratings' detailed report:
In recent trading, shares of AnaptysBio Inc have crossed above the average analyst 12-month target price of $82.71, changing hands for $84.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Top-line Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017
Novel Anti-IL-36 Receptor Antibody for the Treatment of Severe Orphan Inflammatory Disorders
Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017
Data Support Rationale for Development of AnaptysBio's Anti-IL-33 Antibody, ANB020, for the Treatment of Severe Adult Peanut Allergy
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.